Division of Gynecologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America.
Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, Johns Hopkins School of Medicine, Baltimore, MD, United States of America.
Gynecol Oncol. 2021 Jan;160(1):322-332. doi: 10.1016/j.ygyno.2020.10.017. Epub 2020 Nov 5.
Uterine serous carcinoma (USC) is an aggressive subtype of endometrial cancer. Multimodality treatment with surgery, radiotherapy, and chemotherapy is commonly used, given its propensity for extrauterine spread, distant recurrences, and poor prognosis. However, the use of molecularly-based therapy is expanding. Here, we review key molecular features of USC, discuss current management, and assess the landscape of novel therapies and combinations.
子宫浆液性癌(USC)是子宫内膜癌的一种侵袭性亚型。鉴于其具有向子宫外扩散、远处复发和预后不良的倾向,通常采用手术、放疗和化疗的多模态治疗。然而,基于分子的治疗方法的应用正在扩大。在这里,我们回顾了 USC 的关键分子特征,讨论了目前的治疗方法,并评估了新型治疗方法和联合治疗的前景。